A Phase 2 Study to Evaluate JCXH-105, an srRNA-based Herpes Zoster Vaccine
Running, not enrolling · Phase 2
Conditions studied: Herpes Zoster (HZ), Infectious Diseases, Shingles
In brief
The goal of this clinical trial is to assess the safety and immunogenicity of an srRNA-based vaccine, JCXH-105, in the prevention of Herpes Zoster (Shingles). Subjects will be randomized to receive either JCXH-105 or Shingrix.
Key facts
- Study ID
- NCT06581575
- Run by
- Immorna Biotherapeutics, Inc.
- People needed
- 467
- Starts
- 2024-10-16
- Expected to finish
- 2026-08-01
- Last updated by the study team
- 2026-04-23
Who can join
Age: 50 and older. Sex: any. Healthy volunteers: accepted.
Where it is running
- Noble Clinical Research — Tucson, Arizona, United States
- Long Beach Research Institute — Long Beach, California, United States
- DM Clinical Research - Chicago — Chicago, Illinois, United States
- Quality Clinical Research — Omaha, Nebraska, United States
- DM Clinical Research - New Jersey — Jersey City, New Jersey, United States
- Delricht Research — Charleston, South Carolina, United States
- Delricht Research — Prosper, Texas, United States
- DM Clinical Research - Sugarland — Sugar Land, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.